These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 6689235)

  • 1. [Retrospective study of the evaluation of peptic ulcer recurrence after 4 weeks of pirenzepin (Gastrozepin) treatment].
    Krempler F; Sandhofer F; Kalk A
    Wien Med Wochenschr; 1983 Nov; 133(21):553-7. PubMed ID: 6689235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of ulcers with pirenzepin. Results from clinic and practice].
    Krempler F; Sandhofer F; Kalk A
    Wien Med Wochenschr; 1982 Sep; 132(18):427-32. PubMed ID: 6760563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirenzepine in the treatment of peptic ulcer disease. Review and commentary.
    Bianchi Porro G; Petrillo M
    Scand J Gastroenterol Suppl; 1982; 72():229-36. PubMed ID: 6753117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of drug therapy on the relapse of peptic ulcers. 1st communication: the effect of acute therapy.
    Ishimori A; Kawamura T; Koizumi F
    Arzneimittelforschung; 1992 Aug; 42(8):1012-5. PubMed ID: 1418071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment and follow-up studies with pirenzepine in duodenal ulcer: a double-blind study.
    Barberani F; Della Spoletina A; Rossi P; Valentini P; Fatale GP
    Int J Tissue React; 1983; 5(3):309-13. PubMed ID: 6360936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment and prevention of recurrence of duodenal ulcer with pirenzepin and cimetidine].
    Eichenberger PM; Giger M; Mattle W; Pelloni S; Müller-Lissner SA; Gonvers JJ; Birchler R; Blum AL
    Schweiz Med Wochenschr; 1982 Jan; 112(1):25-30. PubMed ID: 7036336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group.
    Asaki S; Sato A; Sakurada H; Takeda T; Hongo M; Toyota T
    J Clin Gastroenterol; 1995; 20 Suppl 2():S56-8. PubMed ID: 7594342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pirenzepine and cimetidine in the treatment of peptic ulcer.
    Brunner H
    Scand J Gastroenterol Suppl; 1982; 72():207-9. PubMed ID: 6957991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of drug therapy on the relapse of peptic ulcers. 2nd communication: the effect of maintenance therapy.
    Ishimori A; Kawamura T; Koizumi F
    Arzneimittelforschung; 1992 Aug; 42(8):1016-9. PubMed ID: 1418072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pirenzepine in the treatment of duodenal ulcer. An endoscopically controlled trial.
    Biomed Pharmacother; 1982; 36(5):266-9. PubMed ID: 6762889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agents with tricyclic structures for treating peptic ulcer disease.
    Berardi RR; Caplan NB
    Clin Pharm; 1983; 2(5):425-31. PubMed ID: 6354568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment of duodenal ulcer with pirenzepine. A double-blind, placebo-controlled trial.
    Dal Monte PR; Bianchi Porro G; Petrillo M; Giuliani-Piccari G; D'Imperio N; Daniotti S
    Scand J Gastroenterol Suppl; 1982; 72():225-8. PubMed ID: 6753116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Results of treatment of peptic ulcers using Gastrozepine and antacids in the endoscopic picture].
    Sorf M; Krislo V; Jablonský I
    Vnitr Lek; 1989 Feb; 35(2):120-5. PubMed ID: 2711618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases.
    Carmine AA; Brogden RN
    Drugs; 1985 Aug; 30(2):85-126. PubMed ID: 3928324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment and relapse prophylaxis of duodenal ulcer with pirenzepine and cimetidine.
    Eichenberger PM; Giger M; Mattle W; Pelloni S; Müller-Lissner SA; Gonvers JJ; Birchler R; Blum AL
    Scand J Gastroenterol Suppl; 1982; 72():197-205. PubMed ID: 6753114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection.
    Labenz J; Börsch G
    Am J Gastroenterol; 1994 Oct; 89(10):1785-8. PubMed ID: 7942667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI.
    Ohara T; Morishita T; Suzuki H; Masaoka T; Ishii H
    Hepatogastroenterology; 2004; 51(56):338-42. PubMed ID: 15086153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of peptic ulcer with gastrozepin].
    Grigor'ev PIa; Khar'kovskiĭ NN; Elina NA; El'tsova NB; Elisova NV
    Sov Med; 1984; (1):48-51. PubMed ID: 6546622
    [No Abstract]   [Full Text] [Related]  

  • 19. Predictors of relapse in peptic ulcer.
    Ishimori A; Kawakami K; Inoue S; Kano A; Takahashi T; Asaki S; Kawamura T; Koizumi F
    Hepatogastroenterology; 1992 Oct; 39(5):396-9. PubMed ID: 1459517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pirenzepin--a new drug in peptic diseases].
    Pavlotzky M; Eshchar J
    Harefuah; 1983 Feb; 104(3):112-6. PubMed ID: 6688601
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.